We are thrilled to share the experience of our first-ever participation in the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting, where we had the opportunity of presenting the study design of our recently launched ANALLISA trial. This event, held in Dublin, Ireland, from October 16-18, marked an important step in MEDSIR’s journey of broadening our clinical trial efforts into the realm of gynecologic oncology.
Opening Session of Day One at the IGCS 2024 Annual Meeting
A platform for learning, networking, and patient-care
The IGCS Annual Meeting is a premier event in gynecologic oncology that brings together experts, clinicians, and researchers from around the world and provides an exceptional platform to showcase the latest advances in research, technology, and clinical practice. The 2024 edition featured a wide array of interdisciplinary sessions, workshops, and networking opportunities, covering topics on surgical oncology, radiation therapy, new therapeutic strategies, and nursing. Among the highlights were key sessions that delved into innovations in early detection of cancer, advancements in targeted therapies, and the evolving role of immunotherapy in treating advanced cancers.
A major focus was placed on global collaboration among professionals dedicated to improving cancer care, not just in terms of scientific advances but also in addressing the burden of gynecological malignancies. These carcinomas remain a major public health challenge given the high rates of morbidity and mortality, particularly in low- and middle-income countries. Emphasizing equitable healthcare, the event spotlighted the importance of global access to diagnostics, fostering partnerships, and improving the lives of women affected by cancers such as ovarian, cervical, or endometrial cancer.
The ANALLISA Trial: addressing oligometastatic progression in ovarian cancer
Our key highlight of the event was the Trial-in-Progress presentation of the ANALLISA study, which introduces a novel approach to addressing the unmet need in treating ovarian cancer patients with oligometastatic progression (OMP). OMP is a challenging stage in which cancer has metastasized but remains confined to a limited number of areas, clinically defined as having fewer than five metastatic lesions. As increasing number of ovarian cancer patients experience OMP following frontline therapy, the optimal subsequent treatment strategy remains uncertain.
The ANALLISA trial is a phase II, single-arm, multicenter study actively recruiting patients at nine institutions across Spain. This study evaluates the efficacy and safety of reintroducing niraparib, a PARP inhibitor (PARPi), in patients with OMP who relapse during or after maintenance PARPi therapy, post-complete secondary cytoreduction. The primary objective of this study is to assess progression-free survival, with additional objectives including overall survival and biomarker-driven responses.
We had the opportunity to chat with Dr. Alfonso Cortés Salgado, principal investigator of the ANALLISA study and medical oncology specialist of breast cancer and gynecological tumors at Hospital Universitario Ramón y Cajal, to discusses the significance of this study. Watch the interview below. You can also delve deeper into the details by downloading the poster here.
Dr. Alfonso Cortés Highlights the ANALLISA Study
Looking ahead for a future of continued growth and innovation
While our roots are in breast cancer research, IGCS 2024 was a significant moment in MEDSIR’s growing mission to improve the lives of patients with difficult-to-treat cancers. Our involvement in gynecologic oncology reflects our dedication to tackling high-burden malignancies that currently have limited treatment options.
Being part of the IGCS 2024 program reinforced commitment and invigorated our vision of advancing oncology research and improving patient outcomes. This event provided not just an opportunity to present our research, but also to learn about current hot topics and emerging trends shaping the field. We thank the IGCS community for welcoming us and expressing interest in our work.
At MEDSIR we are committed to advancing the fight against cancer, one breakthrough at a time and we are excited for what the future holds! Stay tuned for more updates on the ANALLISA study as we continue to expand our clinical trials into new cancer indications. If you are interested in participating in or learning more about the ANALLISA trial, please contact us for further information.
Comments